Vivek Subbiah: Incredible meeting of the Early Phase Drug Development minds

Vivek Subbiah shared on LinkedIn:

“Wow! Incredible meeting of the Early Phase Drug Development minds. Exhilarating discussions on what’s next in oncology with the amazing Dr. Johanna Bendell and team from Roche and our terrific Marcy Vallone Sarah Cannon Research Institute!

We need some direct flights from Nashville to Europe!”

Source: Vivek Subbiah/LinkedIn

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute. He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. Dr. Subbiah’s research interests include drug development in rare cancers, immunotherapy, and radiopharmaceuticals.